Utilization, cost, and prescription patterns of dupilumab among Medicare beneficiaries in the United States from 2017 to 2019

J Dermatolog Treat. 2022 Dec;33(8):3214-3215. doi: 10.1080/09546634.2022.2127304. Epub 2022 Sep 26.

Authors

Michael J Murphy¹, Shayan Cheraghlou², William Damsky^{3

4}, Jeffrey M Cohen³

Affiliations

¹ Yale School of Medicine, New Haven, CT, USA.
² The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, NY, USA.
³ Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.
⁴ Department of Pathology, Yale School of Medicine, New Haven, CT, USA.

PMID: 36137225
DOI: 10.1080/09546634.2022.2127304

No abstract available

MeSH terms

Aged
Antibodies, Monoclonal, Humanized* / therapeutic use
Humans
Medicare*
Prescriptions
United States

Substances

dupilumab
Antibodies, Monoclonal, Humanized